Karyopharm Therapeutics (KPTI) vs Lisata Therapeutics (LSTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Lisata Therapeutics (LSTA) has outperformed Karyopharm Therapeutics (KPTI) over the past year, losing 52.6% versus a loss of 89.8%. Over five years, LSTA leads with a -93.4% price change compared with -99.3% for KPTI. Karyopharm Therapeutics is the larger company by market cap ($13.6 million vs $13.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KPTI | LSTA |
|---|---|---|
| Share price | $0.60 | $1.20 |
| Market cap | $13.61M | $12.96M |
| 1-day change | -6.98% | +2.56% |
| YTD return | -91.85% | -35.48% |
| 1-year return | -89.83% | -52.57% |
| 5-year return | -99.28% | -93.44% |
| EPS (TTM) | $-14.33 | $-1.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.99 | $5.07 |
| 52-week low | $0.60 | $0.99 |
| Distance from 52-week high | -94.54% | -76.33% |
| Analyst consensus | none | none |
| Avg. price target upside | +1108.33% | — |
| Average volume | 1.71M | 291.91K |
| Shares outstanding | 22.68M | 10.80M |
| Employees | 228 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LSTA has outperformed KPTI by 37.3 percentage points over the past year.
About Karyopharm Therapeutics
KPTI stock →Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Health Care · Biotechnology: Pharmaceutical Preparations · 228 employees
About Lisata Therapeutics
LSTA stock →Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
KPTI vs LSTA FAQ
Which is bigger, Karyopharm Therapeutics or Lisata Therapeutics?
Karyopharm Therapeutics (KPTI) is larger, with a market capitalization of $13.61M compared with $12.96M for Lisata Therapeutics (LSTA).
Which stock has performed better over the past year, KPTI or LSTA?
LSTA returned -52.57% over the past 12 months, compared with -89.83% for KPTI (price return, excluding dividends). Past performance does not predict future results.
Are Karyopharm Therapeutics and Lisata Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.